23rd Apr 2015 07:03
LONDON (Alliance News) - GW Pharmaceuticals PLC Thursday said new data from physician reports with 137 children and young adults with treatment-resistant epilepsy treated with epidiolex further reinforces and supports signs of the treatments efficacy.
The data was presented at the American Academy of Neurology annual meeting in Washington DC. The data showed that epidiolex was associated with "meaningful reductions" in seizures across a range of childhood epilepsies, and a sustained response over a six month period. 90% of the patients remained on the treatment.
"We believe that these findings fully support our decision to advance Epidiolex into Phase 3 placebo-controlled, double-blind trials in Dravet syndrome and Lennox-Gastaut syndrome and we look forward to advancing these trials rapidly during 2015," said Chief Executive Justin Gover in a statement.
The company will also explore the use of epidiolex to treat Tuberous Sclerosis Complex, a genetic disorder that causes non-malignant tumours to form in many different organs which commonly causes epilepsy. A number of patients with the disorder have been treated with epidiolex as part of an expanded access programme, and of the five patients treated four saw a reduction in seizures of 97% at week sixteen compared to a four week baseline period.
All three patients with cognitive impairments experienced cognitive gains, and one of the two subjects with behavioural problems showed improvements, GW said.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L